3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
2
Phase 2
2
Status
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
2
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
83
Cyclophosphamide
55
Specimen Handling
54
Carboplatin
53
fludarabine
44
Nivolumab
43
Magnetic Resonance Spectroscopy
43
Gemcitabine
41
Biopsy
40
venetoclax
33
Bevacizumab
33
Dexamethasone
31
Paclitaxel
29
Pemetrexed
27
Injections
27
Cisplatin
27
Docetaxel
26
Azacitidine
22
atezolizumab
21
Rituximab
21
Oxaliplatin
21
Capecitabine
21
Lenalidomide
20
Ipilimumab
20
Temozolomide
19
Fulvestrant
19
Cetuximab
19
abemaciclib
18
Fluorouracil
18
Cytarabine
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
R-CHOP protocol
×
90 days
×
Clear all
NCT04661007
2026-05-18
J-MIND
Incyte Corporation
Phase 1/2
Active not recruiting
72 enrolled
NCT04542824
2026-05-05
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-05-05
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled